• Clinical and Experimental Pediatrics
• /
• 제58권8호
• /
• pp.309-312
• /
• 2015

Permanent neonatal diabetes mellitus refers to diabetes that occurs before the age of 6 months and persists through life. It is a rare disorder affecting one in 0.2-0.5 million live births. Mutations in the gene KCNJ11, encoding the subunit Kir6.2, and ABCC8, encoding SUR1 of the ATP-sensitive potassium ($K_{ATP}$) channel, are the most common causes of permanent neonatal diabetes mellitus. Sulfonylureas close the $K_{ATP}$ channel and increase insulin secretion. KCNJ11 and ABCC8 mutations have important therapeutic implications because sulfonylurea therapy can be effective in treating patients with mutations in the potassium channel subunits. The mutation type, the presence of neurological features, and the duration of diabetes are known to be the major factors affecting the treatment outcome after switching to sulfonylurea therapy. More than 30 mutations in the KCNJ11 gene have been identified. Here, we present our experience with a patient carrying a novel p.H186D heterozygous mutation in the KCNJ11 gene who was successfully treated with oral sulfonylurea.

• Neonatal Medicine
• /
• 제28권2호
• /
• pp.94-98
• /
• 2021

Neonatal diabetes mellitus (NDM) is a rare disease that occurs at less than 6 months of age and is presumably caused by a mutation in the gene that affects pancreatic beta-cell function. Approximately 80% of NDM cases reveal a known genetic mutation, and mutations in potassium inwardly rectifying channel subfamily J member 11 (KCNJ11) and ABCC8 affecting the pancreatic beta-cell adenosine triphosphate-sensitive potassium channel may be treated with oral sulfonylurea. Early recognition of mutations in KCNJ11 and ABCC8 is important because early administration of sulfonylurea can not only control blood glucose levels but also improve neurodevelopmental outcomes. In the present study, we report a case of NDM that initially presented as diabetic ketoacidosis at the age of 1 month, accompanied by seizures during hospitalization. After confirmation of the KCNJ11 gene mutation (c.989A>C), we started administering oral sulfonylurea (glimepiride) at the age of 2 months. After gradually increasing the dosage of glimepiride, insulin was discontinued at the age of 3 months. To date, the infant's blood glucose levels have been well controlled without significant hypoglycemic events. No further episodes of seizures have occurred, and his developmental status is favorable.

• 생명과학회지
• /
• 제20권3호
• /
• pp.457-461
• /
• 2010

가족성 저칼륨성 주기성마비는 간헐적으로 발생하는 저칼륨혈증을 동반한 가역적 이완성 근육마비를 특정으로 하는 상염색체 우성 유전질환이다. 골격근 세포막에 위치한 $K_{ATP}$ 채널의 활성도 감소가 저칼륨성 주기성 마비의 발병과 관련 있는 것으로 보고되고 있으나 아직까지 명확한 기전이 밝혀져 있지 않다. 본 연구에서는 $K_{ATP}$ 채널을 구성하는 단위체인 Kir6.2를 대상으로 가족성 저칼륨성 주기성마비 환자의 골격근 세포에서 $K_{ATP}$ 채널의 활성도 감소가 발생하는 분자생물학적 기전을 알아보고자 하였다. 환자와 정상인의 골격근 세포내 Kir6.2 단위체의 유전자인 KCNJ11 의 mRNA발현 수준과 단백질 발현양상을 확인한 결과, 정상 세포외 칼륨 농도인 4mM 칼륨 완충용액에 노출된 경우 KCNJ11 mRNA와 단백질 수준의 정량적 차이는 관찰되지 않았다. 그러나 환자에서 마비를 유발할 수 있는 저칼륨 농도인 1mM의 칼륨 완충용액에 노출시킨 경우 정상세포는 KCNJ11 mRNA의 발현이 감소하였고, 그 산물인 Kir6.2 단백질의 정량적 차이를 확인한 결과 세포막에 존재하는 단백질의 양 또한 유의하게 감소하였다. 그러나 환자의 경우 1mM의 칼륨 완충용액에 노출시 KCNJ11 mRNA 발현수준에 차이가 없었고, 더불어 세포막과 세포질 상의 Kir6.2 단백질 분포에도 변화가 나타나지 않았다. 이는 환자 세포의 경우 세포막 단백질이 세포질로 회수되지 못하여 $K_{ATP}$ 채널의 폐쇄가 유지되어 탈분극이 지속되며 이로 인해 환자에서 마비 증상을 유발할 수 있음을 시사하는 결과로 본 질환의 새로운 발병 기전을 설명할 수 있는 근거로 생각된다.

• 대한유전성대사질환학회지
• /
• 제6권1호
• /
• pp.52-57
• /
• 2006

Permanent neonatal diabetes(PND) is a rare form of diabetes characterized by insulin-requiring hyperglycemia that is diagnosed within the first 3 months of life. In most cases, the causes are not known. Recently, mutations in the gene KCNJ11 encoding the Kir6.2 subunit of the ATP-sensitive K+ charmel have been described in patients with PND. We report a child with PND due to a lysine-to-arginine substitution at position 170(K170R) of gene encoding Kir6.2 Our patient was diagnosed at 7 weeks of age and had been treated with subcutaneous insulin for 6.5 years. Recently, our patient has been changed from subcutaneous insulin to oral glibenclamide therapy at a daily dose of 7.5 mg 3 times a day(0.9 mg/kg/day) at the age of 6.5 years. Before glibenclamide therapy, c-peptide level was 0.1 ng/ml(normal 1.0-3.5 ng/ml) and hemoglobin HbA1c level was 7.8%(normal <6%). After 6 days of treatment, her c-peptide and insulin levels were 2.3 ng/ml and $9.6{\mu}U/ml$(normal $5-25{\mu}U/ml$), respectively. After 1 month later, the insulin and c-peptide levels were in the nonnal range without any episodes of hyper- or hypoglycemia. This case demonstrated that oral sulfonylurea may be the treatment of choice in PND patients with KCNJ11 mutation even at a young age.

• Clinical and Experimental Pediatrics
• /
• 제59권sup1호
• /
• pp.116-120
• /
• 2016

Congenital hyperinsulinism (CHI) is a rare condition that can cause irreversible brain damage during the neonatal period owing to the associated hypoglycemia. Hypoglycemia in CHI occurs secondary to the dysregulation of insulin secretion. CHI has been established as a genetic disorder of islet-cell hyperplasia, associated with a mutation of the ABCC8 or KCNJ11 genes, which encode the sulfonylurea receptor 1 and the inward rectifying potassium channel (Kir6.2) subunit of the ATP-sensitive potassium channel, respectively. We report the case of a female newborn infant who presented with repetitive seizures and episodes of apnea after birth, because of hypoglycemia. Investigations revealed hypoglycemia with hyperinsulinemia, but no ketone bodies, and a low level of free fatty acids. High dose glucose infusion, enteral feeding, and medications could not maintain the patient's serum glucose level. Genetic testing revealed a new variation of ABCC8 mutation. Therefore, we report this case of CHI caused by a novel mutation of ABCC8 in a half-Korean newborn infant with diazoxide-unresponsive hyperinsulinemic hypoglycemia.

• The Korean Journal of Physiology and Pharmacology
• /
• 제27권1호
• /
• pp.85-94
• /
• 2023

Ion channels regulate a large number of cellular functions and their functional role in many diseases makes them potential therapeutic targets. Given their diverse distribution across multiple organs, the roles of ion channels, particularly in age-associated transcriptomic changes in specific organs, are yet to be fully revealed. Using RNA-seq data, we investigated the rat transcriptomic profiles of ion channel genes across 11 organs/tissues and 4 developmental stages in both sexes of Fischer 344 rats and identify tissue-specific and age-dependent changes in ion channel gene expression. Organ-enriched ion channel genes were identified. In particular, the brain showed higher tissue-specificity of ion channel genes, including Gabrd, Gabra6, Gabrg2, Grin2a, and Grin2b. Notably, age-dependent changes in ion channel gene expression were prominently observed in the thymus, including in Aqp1, Clcn4, Hvcn1, Itpr1, Kcng2, Kcnj11, Kcnn3, and Trpm2. Our comprehensive study of ion channel gene expression will serve as a primary resource for biological studies of aging-related diseases caused by abnormal ion channel functions.

• Genomics & Informatics
• /
• 제12권4호
• /
• pp.283-288
• /
• 2014

Among all serious diseases globally, diabetes (type 1 and type 2) still poses a major challenge to the world population. Several target proteins have been identified, and the etiology causing diabetes has been reasonably well studied. But, there is still a gap in deciding on the choice of a drug, especially when the target is mutated. Mutations in the KCNJ11 gene, encoding the kir6.2 channel, are reported to be associated with congenital hyperinsulinism, having a major impact in causing type 1 diabetes, and due to the lack of its 3D structure, an attempt has been made to predict the structure of kir6.2, applying fold recognition methods. The current work is intended to investigate the affinity of four phytochemicals namely, curcumin (Curcuma longa), genistein (Genista tinctoria), piperine (Piper nigrum), and pterostilbene (Vitis vinifera) in a normal as well as in a mutant kir6.2 model by adopting a molecular docking methodology. The phytochemicals were docked in both wild and mutated kir6.2 models in two rounds: blind docking followed by ATP-binding pocket-specific docking. From the binding pockets, the common interacting amino acid residues participating strongly within the binding pocket were identified and compared. From the study, we conclude that these phytochemicals have strong affinity in both the normal and mutant kir6.2 model. This work would be helpful for further study of the phytochemicals above for the treatment of type 1 diabetes by targeting the kir6.2 channel.